Anti-Hypertensive Medications and Cardiovascular Events in Older Adults with Multiple Chronic Conditions

Abstract

ImportanceRandomized trials of anti-hypertensive treatment demonstrating reduced risk of cardiovascular events in older adults included participants with less comorbidity than clinical populations. Whether these results generalize to all older adults, most of whom have multiple chronic conditions, is uncertain.ObjectiveTo determine the association between anti-hypertensive medications and CV events and mortality in a nationally representative population of older adults.DesignCompeting risk analysis with propensity score adjustment and matching in the Medicare Current Beneficiary Survey cohort over three-year follow-up through 2010.Participants and Setting4,961 community-living participants with hypertension.ExposureAnti-hypertensive medication intensity, based on standardized daily dose for each anti-hypertensive medication class participants used.Main Outcomes and MeasuresCardiovascular events (myocardial infarction, unstable angina, cardiac revascularization, stroke, and hospitalizations for heart failure) and mortality.ResultsOf 4,961 participants, 14.1% received no anti-hypertensives; 54.6% received moderate, and 31.3% received high, anti-hypertensive intensity. During follow-up, 1,247 participants (25.1%) experienced cardiovascular events; 837 participants (16.9%) died. Of deaths, 430 (51.4%) occurred in participants who experienced cardiovascular events during follow-up. In the propensity score adjusted cohort, after adjusting for propensity score and other covariates, neither moderate (adjusted hazard ratio, 1.08 [95% CI, 0.89–1.32]) nor high (1.16 [0.94–1.43]) anti-hypertensive intensity was associated with experiencing cardiovascular events. The hazard ratio for death among all participants was 0.79 [0.65–0.97] in the moderate, and 0.72 [0.58–0.91] in the high intensity groups compared with those receiving no anti-hypertensives. Among participants who experienced cardiovascular events, the hazard ratio for death was 0.65 [0.48–0.87] and 0.58 [0.42–0.80] in the moderate and high intensity groups, respectively. Results were similar in the propensity score-matched subcohort.Conclusions and RelevanceIn this nationally representative cohort of older adults, anti-hypertensive treatment was associated with reduced mortality but not cardiovascular events. Whether RCT results generalize to older adults with multiple chronic conditions remains uncertain.

Carotid atherosclerosis and cardiovascular health metrics in old subjects from the AGES-Reykjavik study

“…21 To our knowledge, the effects of cardiovascular medical treatment on atherosclerosis progression in older subjects (>65 years) have not been investigated. However studies suggest that subjects in this age group may benefit from treatment 14, 22–25 . In the AGES-Reykjavik study, statin use was associated with 16% lower cardiovascular mortality, albeit not statistically significant, and 30% lower all-cause mortality in subjects without diabetes.…”

Comparative effectiveness of antihypertensive drugs in nondiabetic patients with hypertension: A population‐based study

“…The time to event was defined as the time from cohort entry to the first of either physician outpatient billing claims or hospital discharges with a primary or secondary diagnosis related to one of the four events described above. 15 For all analyses, we looked for the first occurrence of the outcome.…”

Tolerability of Antihypertensive Medications in Older Adults

“…As the activity of the renin-angiotensin system declines with age, the efficacy of drugs targeting the RAAS system may be lower [97]. In a sample of nearly 5000 community-dwelling older adults with multiple chronic conditions, antihypertensive treatment was associated with reduced mortality but not cardiovascular events (myocardial infarction, angina, stroke, and HF hospitalizations) [189]. The American Geriatrics Society Beers Criteria for potentially inappropriate medication use in older adults suggests the avoidance of a-blockers for hypertension because of risk for orthostatic hypotension; it discourages the use of clonidine as a first-line antihypertensive agent due to adverse central nervous system effects [190].…”